首页> 外文会议>International Conference on Science and Technology >Utilization of Flavonoid Compounds as HER2 Tyrosine Kinase Inhibitor in Breast Cancer Using Fragment-Based Drug Design
【24h】

Utilization of Flavonoid Compounds as HER2 Tyrosine Kinase Inhibitor in Breast Cancer Using Fragment-Based Drug Design

机译:使用碎片的药物设计在乳腺癌中用黄酮类化合物作为HER2酪氨酸激酶抑制剂

获取原文

摘要

Breast cancer has become one of the leading cause of women's death around the world. Breast cancer can be caused by genetic or environmental factors. Human epidermal growth factor receptor 2 (HER2) is one of the main causes of breast cancer. The HER2 tyrosine kinase plays a significant role in the dimerization reaction which causes auto-phosphorylation of tyrosine residues in the cytoplasmic domain that triggers the growth of the cancer cells. Inhibition of HER2 protein activity can be a potential alternative for breast cancer treatment. Flavonoids have become an important scaffold in medicinal chemistry due to its bioactivity and availability. Therefore, flavonoids were used as the database on this in silico research. Fragment-based drug design was applied to determine novel drug candidates. Three potential candidates were obtained in this research. VC-255 was selected as the best inhibitor candidates for HER2 tyrosine kinase.
机译:乳腺癌已成为妇女在世界上死亡的主要原因之一。乳腺癌可能是由遗传或环境因素引起的。人表皮生长因子受体2(HER2)是乳腺癌的主要原因之一。 HER2酪氨酸激酶在二聚化反应中起着重要作用,导致细胞质结构域中的酪氨酸残基的自磷酸化,其触发癌细胞的生长。抑制HER2蛋白活性可以是乳腺癌治疗的潜在替代品。由于其生物活性和可用性,黄酮类化合物已成为药物化学中的重要支架。因此,在Silico研究中使用黄酮类化合物作为数据库。施用基于片段的药物设计来确定新型毒品候选者。在这项研究中获得了三个潜在的候选者。选择VC-255作为HER2酪氨酸激酶的最佳抑制剂候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号